ValuEngine upgraded shares of Becton Dickinson (NYSE:BDX) from a hold rating to a buy rating in a research note issued to investors on Wednesday.
BDX has been the topic of a number of other research reports. Zacks Investment Research downgraded Becton Dickinson from a buy rating to a hold rating in a report on Friday, January 5th. Deutsche Bank set a $260.00 target price on Becton Dickinson and gave the company a buy rating in a report on Friday, December 29th. KeyCorp initiated coverage on Becton Dickinson in a research report on Friday, January 5th. They issued an overweight rating and a $260.00 price target for the company. Citigroup upgraded Becton Dickinson from a sell rating to a neutral rating in a research report on Friday, January 5th. Finally, Evercore ISI initiated coverage on Becton Dickinson in a research report on Wednesday, January 3rd. They issued an outperform rating and a $245.00 price target for the company. Five research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $241.19.
BDX stock opened at $234.39 on Wednesday. Becton Dickinson has a fifty-two week low of $175.66 and a fifty-two week high of $248.39. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.93 and a current ratio of 1.54. The stock has a market capitalization of $62,148.98, a price-to-earnings ratio of 24.22, a PEG ratio of 1.69 and a beta of 1.15.
The business also recently declared a quarterly dividend, which was paid on Friday, March 30th. Shareholders of record on Friday, March 9th were given a $0.75 dividend. This represents a $3.00 dividend on an annualized basis and a yield of 1.28%. The ex-dividend date was Thursday, March 8th. Becton Dickinson’s payout ratio is 31.65%.
In related news, EVP Thomas E. Polen, Jr. sold 1,877 shares of the stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $227.00, for a total transaction of $426,079.00. Following the completion of the sale, the executive vice president now owns 15,387 shares in the company, valued at $3,492,849. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP James W. Borzi sold 4,048 shares of the stock in a transaction dated Monday, February 26th. The stock was sold at an average price of $224.98, for a total value of $910,719.04. Following the sale, the executive vice president now owns 5,334 shares of the company’s stock, valued at approximately $1,200,043.32. The disclosure for this sale can be found here. Insiders have sold 281,108 shares of company stock valued at $61,321,396 in the last quarter. 1.00% of the stock is currently owned by company insiders.
Large investors have recently added to or reduced their stakes in the stock. Legacy Advisors LLC grew its position in shares of Becton Dickinson by 7,000.0% during the fourth quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock worth $106,000 after purchasing an additional 490 shares in the last quarter. Amica Retiree Medical Trust grew its position in shares of Becton Dickinson by 325.0% during the fourth quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock worth $109,000 after purchasing an additional 390 shares in the last quarter. Almanack Investment Partners LLC. purchased a new position in Becton Dickinson during the 4th quarter valued at approximately $109,000. FTB Advisors Inc. grew its holdings in Becton Dickinson by 114.2% during the 4th quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock valued at $116,000 after buying an additional 290 shares in the last quarter. Finally, Advisors Preferred LLC purchased a new position in Becton Dickinson during the 4th quarter valued at approximately $126,000. Hedge funds and other institutional investors own 83.46% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Becton Dickinson (BDX) Upgraded to “Buy” at ValuEngine” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://stocknewstimes.com/2018/04/19/becton-dickinson-bdx-upgraded-to-buy-at-valuengine.html.
About Becton Dickinson
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Becton Dickinson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and related companies with MarketBeat.com's FREE daily email newsletter.